Table 2.

Staining intensity of tumor markers in PTC, controls and FED

Group		n	CK19			Galectin-3			HBME-1
			0	1+	2+~3+	0	1+	2+~3+	0	1+	2+~3+
PTC	hptc	26	0	2	24	2	14	10	5	10	11
	ptc	17	0	2	15	0	10	7	1	2	14*
C		16	9	5	2	16	0	0	16	0	0
FED		18	0	13	5Δ	11	7	0☆	16	2	0☆
Group		n	CD56			Claudin-1			NGAL
			0	1+	2+~3+	0	1+	2+~3+	0	1+	2+~3+
PTC	hptc	26	19	5	2	2	6	18	1	5	20
	ptc	17	15	2	0	2	1	14	2	2	13
Control		16	0	0	16	16	0	0	16	0	0
FED		18	1	4	13☆	5	13	0Δ	5	8	5Δ

Abbreviation: No., the number of cases; PTC, all papillary thyroid carcinoma; hptc, papillary thyroid carcinoma coexisted with Hashimoto’s thyroiditis; ptc, papillary thyroid carcinoma without Hashimoto’s thyroiditis; Control, benign thyroid tissues; FED, follicular epithelial dysplasia showing PTC-like nuclear alterations in Hashimoto’s thyroiditis;

^*compared with hptc, P = 0.031;

^Δcompared with PTC and C, all P < 0.001;

^☆compared with PTC, all P < 0.01.